Medpace Posts Better Than Expected Q1 Earnings, Lifts FYY22 Profit Outlook

  • Medpace Holdings Inc's MEDP Q1 revenue increased 27.3% Y/Y to $330.9 million, beating the consensus of $327.09 million. On a constant currency organic basis, revenue increased 28.1%.
  • As of March 31, 2022, the Backlog grew 28% to $2.1 billion. Net new business awards were $423 million, representing a net book-to-bill ratio of 1.28x.
  • EBITDA increased 31.3% to $70.4 million or 21.3% of revenue, compared to $53.6 million, or 20.6% of revenue a year ago.
  • Medpace posted EPS of $1.69, up from $1.1435 posted a year ago and beating the consensus of $1.26.
  • Financial Guidance: Medpace reaffirmed FY22 revenue of $1.4 billion - $1.46 billion, representing Y//Y growth of 22.6% - 27.8%, compared to the consensus of $1.41 billion.
  • EBITDA is expected to be $262 million - $278 million. 
  • Medpace expects EPS of $5.72 - $6.06, compared to prior guidance of $5.35 - $5.67 and the consensus of $5.61.
  • Price Action: MEDP shares are down 8.76% at $135.04 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!